Panion & BF Biotech Inc (TW:1760) — Market Cap & Net Worth
Market Cap & Net Worth: Panion & BF Biotech Inc (1760)
Panion & BF Biotech Inc (TW:1760) has a market capitalization of $184.23 Million (NT$5.85 Billion) as of May 4, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16847 globally and #833 in its home market, demonstrating a 5.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Panion & BF Biotech Inc's stock price NT$68.20 by its total outstanding shares 85739000 (85.74 Million). Analyse Panion & BF Biotech Inc (1760) cash flow conversion to see how efficiently the company converts income to cash.
Panion & BF Biotech Inc Market Cap History: 2015 to 2026
Panion & BF Biotech Inc's market capitalization history from 2015 to 2026. Data shows change from $614.90 Million to $184.23 Million (-10.81% CAGR).
Panion & BF Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Panion & BF Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Panion & BF Biotech Inc's market cap is 0.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.78x
Panion & BF Biotech Inc's market cap is 1.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $614.90 Million | $1.21 Billion | $73.00 Million | 0.51x | 8.42x |
| 2016 | $161.47 Million | $1.05 Billion | $89.72 Million | 0.15x | 1.80x |
| 2017 | $178.82 Million | $1.21 Billion | $90.54 Million | 0.15x | 1.98x |
| 2018 | $204.52 Million | $1.41 Billion | $159.17 Million | 0.15x | 1.28x |
| 2019 | $214.31 Million | $1.57 Billion | $161.33 Million | 0.14x | 1.33x |
| 2020 | $215.29 Million | $1.57 Billion | $27.90 Million | 0.14x | 7.72x |
| 2021 | $194.31 Million | $1.90 Billion | $104.40 Million | 0.10x | 1.86x |
| 2022 | $468.95 Million | $2.40 Billion | $182.34 Million | 0.20x | 2.57x |
| 2023 | $297.93 Million | $1.88 Billion | $77.22 Million | 0.16x | 3.86x |
| 2024 | $221.77 Million | $2.03 Billion | $124.52 Million | 0.11x | 1.78x |
Competitor Companies of 1760 by Market Capitalization
Companies near Panion & BF Biotech Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Panion & BF Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Panion & BF Biotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Panion & BF Biotech Inc's market cap moved from $614.90 Million to $ 184.23 Million, with a yearly change of -10.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$184.23 Million | +8.25% |
| 2025 | NT$170.18 Million | -23.26% |
| 2024 | NT$221.77 Million | -25.56% |
| 2023 | NT$297.93 Million | -36.47% |
| 2022 | NT$468.95 Million | +141.34% |
| 2021 | NT$194.31 Million | -9.75% |
| 2020 | NT$215.29 Million | +0.46% |
| 2019 | NT$214.31 Million | +4.79% |
| 2018 | NT$204.52 Million | +14.37% |
| 2017 | NT$178.82 Million | +10.74% |
| 2016 | NT$161.47 Million | -73.74% |
| 2015 | NT$614.90 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Panion & BF Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $184.23 Million USD |
| MoneyControl | $184.23 Million USD |
| MarketWatch | $184.23 Million USD |
| marketcap.company | $184.23 Million USD |
| Reuters | $184.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Panion & BF Biotech Inc
Panion & Bf Biotech Inc., a biotechnology pharmaceutical company, provides western medicines, cosmetics, testing reagents, food and chemical products in Taiwan, the United States, China, Hong Kong, Macau, and internationally. The company offers products in the areas of antibody, respiratory, gastrointestinal, COVID-19 IVD, antigen, anti-aging, active pharmaceutical ingredients, disease treatment,… Read more